Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,257.26
+1.0%		$1,180.14
$694.23
▼
$1,292.65
$1.18T0.512.83 million shs2.50 million shs
Natera, Inc. stock logo
NTRA
Natera
$332.03
+2.2%		$274.24
$157.43
▼
$333.56
$47.86B1.511.44 million shs1.21 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+6.35%+6.07%+17.88%+78.40%
Natera, Inc. stock logo
NTRA
Natera
0.00%+7.13%+25.44%+63.41%+106.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,257.26
+1.0%		$1,180.14
$694.23
▼
$1,292.65
$1.18T0.512.83 million shs2.50 million shs
Natera, Inc. stock logo
NTRA
Natera
$332.03
+2.2%		$274.24
$157.43
▼
$333.56
$47.86B1.511.44 million shs1.21 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+6.35%+6.07%+17.88%+78.40%
Natera, Inc. stock logo
NTRA
Natera
0.00%+7.13%+25.44%+63.41%+106.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,292.182.78% Upside
Natera, Inc. stock logo
NTRA
Natera
2.82
Moderate Buy$319.38-3.81% Downside

Current Analyst Ratings Breakdown

Latest LLY and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$315.00 ➝ $365.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$305.00 ➝ $350.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $360.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$249.00 ➝ $363.50
8/11/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/10/2026
Natera, Inc. stock logo
NTRA
Natera
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$355.00
8/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$1,376.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $340.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$275.00 ➝ $350.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$348.00
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B18.16$25.18 per share49.94$35.99 per share34.93
Natera, Inc. stock logo
NTRA
Natera
$2.31B20.75N/AN/A$12.64 per share26.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8042.1927.411.4833.53%97.83%23.23%10/29/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A33,203.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)

Latest LLY and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.55%+15.18%23.22%11 Years
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A

Latest LLY and NTRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.59%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Natera, Inc. stock logo
NTRA
Natera
5.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable

Recent News About These Companies

Pinnbrook Capital Management LP Purchases Shares of 69,300 Natera, Inc. $NTRA
August 23 at 6:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pinnbrook-capital-management-lp-purchases-shares-of-69300-natera-inc-ntra-2026-08-23/
3,878 Shares in Natera, Inc. $NTRA Acquired by Allworth Financial LP
August 23 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3878-shares-in-natera-inc-ntra-acquired-by-allworth-financial-lp-2026-08-23/
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts (NTRA)
...
August 22 at 11:00 AM  |  marketbeat.comhttps://www.marketbeat.com/articles/2-biotech-stocks-shaping-up-for-major-breakouts/
Westpac Banking Corp Buys Shares of 10,214 Natera, Inc. $NTRA
August 22 at 6:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-westpac-banking-corp-buys-shares-of-10214-natera-inc-ntra-2026-08-22/
Ieq Capital LLC Purchases Shares of 148,901 Natera, Inc. $NTRA
August 22 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ieq-capital-llc-purchases-shares-of-148901-natera-inc-ntra-2026-08-22/
Robinhood Asset Management LLC Makes New Investment in Natera, Inc. $NTRA
August 22 at 6:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-robinhood-asset-management-llc-makes-new-investment-in-natera-inc-ntra-2026-08-22/
8,241 Shares in Natera, Inc. $NTRA Acquired by Keebeck Wealth Management
August 22 at 5:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-8241-shares-in-natera-inc-ntra-acquired-by-keebeck-wealth-management-2026-08-22/
NewEdge Wealth LLC Invests $1.34 Million in Natera, Inc. $NTRA
August 22 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-newedge-wealth-llc-invests-134-million-in-natera-inc-ntra-2026-08-22/
Encore Global Management LP Invests $1.63 Million in Natera, Inc. $NTRA
August 22 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-encore-global-management-lp-invests-163-million-in-natera-inc-ntra-2026-08-22/
Virtus Advisers LLC Takes $1.01 Million Position in Natera, Inc. $NTRA
August 21 at 6:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virtus-advisers-llc-takes-101-million-position-in-natera-inc-ntra-2026-08-21/
Silvant Capital Management LLC Takes $12.32 Million Position in Natera, Inc. $NTRA
August 21 at 6:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-silvant-capital-management-llc-takes-1232-million-position-in-natera-inc-ntra-2026-08-21/
Ninepoint Partners LP Purchases New Position in Natera, Inc. $NTRA
August 21 at 6:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ninepoint-partners-lp-purchases-new-position-in-natera-inc-ntra-2026-08-21/
D L Carlson Investment Group Inc. Makes New $3.49 Million Investment in Natera, Inc. $NTRA
August 21 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-d-l-carlson-investment-group-inc-makes-new-349-million-investment-in-natera-inc-ntra-2026-08-21/
Danske Bank A S Makes New Investment in Natera, Inc. $NTRA
August 21 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-danske-bank-a-s-makes-new-investment-in-natera-inc-ntra-2026-08-21/
Deutsche Bank AG Purchases Shares of 320,037 Natera, Inc. $NTRA
August 21 at 3:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-purchases-shares-of-320037-natera-inc-ntra-2026-08-21/
Natera, Inc. (NASDAQ:NTRA) Given Average Recommendation of "Moderate Buy" by Brokerages
August 21 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973562
Natera, Inc. (NASDAQ:NTRA) Receives Consensus Rating of "Moderate Buy" from Analysts
August 21 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-inc-nasdaqntra-receives-consensus-rating-of-moderate-buy-from-analysts-2026-08-21/
Natera (NASDAQ:NTRA) Reaches New 1-Year High - Time to Buy?
August 20 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-nasdaqntra-reaches-new-1-year-high-time-to-buy-2026-08-20/
Mitsubishi UFJ Asset Management Co. Ltd. Takes $50.42 Million Position in Natera, Inc. $NTRA
August 20 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-mitsubishi-ufj-asset-management-co-ltd-takes-5042-million-position-in-natera-inc-ntra-2026-08-20/
Edmond DE Rothschild Holding S.A. Takes Position in Natera, Inc. $NTRA
August 20 at 4:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-edmond-de-rothschild-holding-sa-takes-position-in-natera-inc-ntra-2026-08-20/
Eagle Health Investments LP Makes New Investment in Natera, Inc. $NTRA
August 20 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eagle-health-investments-lp-makes-new-investment-in-natera-inc-ntra-2026-08-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,257.26 +12.86 (+1.03%)
As of 08/21/2026 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Natera stock logo

Natera NASDAQ:NTRA

$332.03 +7.19 (+2.21%)
As of 08/21/2026 04:00 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas